Digesting 2022 and looking forward to 2023 in IBD therapeutics

The past year has seen quite a few new developments in inflammatory bowel disease therapy.The SEAVUE head-to-head trial of ustekinumab vs. adalimumab for Crohn’s disease demonstrated that both biologics were highly effective in inducing clinical remission in biologic-naïve patients with moderate to severe activity. The SERENE trials showed that a higher induction dose of Humira (adalimumab, AbbVie) was no more effective than the standard induction dose for inducing clinical remission in both ulcerative colitis and CD. A higher maintenance dose (40 mg weekly) was slightly moreRead More

Generated by Feedzy